Teva Pharmaceutical Industries — TEVA
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $31.00 | $35.57B | 50.8 | 11.2 | 21.8% | 5.3% | - | 4.9 |
Latest Headlines
- · J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
- · Where is Teva Pharmaceutical Industries Limited (TEVA) Headed?
- · Teva And Sanofi Data Add Potential Branded Growth Option In IBD
- · Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
- · Corcept's Q4 Earnings and Revenues Fall Short of Estimates
- · Corcept Therapeutics Q4 Earnings Call Highlights
Revenue & Net Income
| Date | Revenue | Net_Income | EPS | Last_Updated | Revenue_Change | Net_Income_Change | EPS_Change | |
|---|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $16,658M | $-3,990M | $-3.64 | 2025-01-30 13:21:22 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $15,879M | $417M | $0.38 | 2025-01-30 13:21:22 | -4.7% | -110.5% | -110.4% |
| 2 | 2022-12-31 | $14,925M | $-2,446M | $-2.12 | 2026-02-27 22:06:12 | -6.0% | -686.6% | -657.9% |
| 3 | 2023-12-31 | $15,845M | $-559M | $-0.50 | 2026-02-27 22:06:12 | 6.2% | -77.1% | -76.4% |
| 4 | 2024-12-31 | $16,544M | $-1,639M | $-1.45 | 2026-02-27 22:06:12 | 4.4% | 193.2% | 190.0% |
| 5 | 2025-12-31 | $17,257M | $1,410M | $1.23 | 2026-02-27 22:06:12 | 4.3% | -186.0% | -184.8% |
| 6 | TTM 2025-12-31 | $17,258M | $1,409M | $1.21 | 2026-02-02 08:33:47 | 0.0% | -0.1% | -1.6% |
EPS
Forecasts
Y/Y % Change
TEVA Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | Average | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | -4.7% | -6.0% | 6.2% | 4.4% | 4.3% | -3.3% | 3.1% | 0.6% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | |
| EPS Growth (%) | -110.5% | -686.6% | -77.1% | 193.2% | -186.0% | 124.7% | 11.8% | -104.4% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | Sales & Marketing ($) | G&A ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|---|---|
| 2021 | $15.9B | $7.0B | $967.0M | $2.4B | $1.1B | $3.5B | $1.3B |
| 2022 | $14.9B | $6.6B | $838.0M | $2.3B | $1.2B | $3.4B | $1.3B |
| 2023 | $15.8B | $7.0B | $953.0M | $2.3B | $1.2B | $3.5B | $1.2B |
| 2024 | $16.5B | $7.4B | $998.0M | $2.5B | $1.2B | $3.7B | $1.1B |
| TTM | $16.8B | $7.4B | $994.0M | $2.6B | $1.2B | $3.8B | $1.0B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | Sales & Marketing Change (%) | G&A Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|---|---|
| 2022 | -6.01 | -4.46 | -13.34 | -6.75 | 7.37 | -2.35 | -1.65 |
| 2023 | 6.16 | 6.07 | 13.72 | 3.13 | -1.53 | 1.54 | -11.85 |
| 2024 | 4.41 | 5.32 | 4.72 | 8.78 | -0.09 | 5.83 | -8.15 |
| TTM | 1.40 | -0.84 | -0.40 | 1.61 | 5.17 | 2.73 | -4.34 |
No unmapped expenses.
Segment Performance
SEGMENTS v2025-09-09 · 2026-02-27 22:06 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
| Year | Prod Rev | Generics Medicians Including Otc And Biosimilars Rev | Distribution Service Rev | Austedo Rev | Anda Rev | Other Products Rev | Product And Service Other Rev | License Rev | Ajovy Rev | C O P A X O N E Rev | Respiratory Product Rev | Bendeka And Treanda Rev | Uzedy Rev | Total Rev |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | 26B | 8.73B | 3.23B | 1.24B | 1.58B | 1.82B | 1.14B | 1.36B | 0.43B | 0.59B | 0.27B | 0.24B | 0.02B | 46.6B |
| 2024 | 28.1B | 9.46B | 3.15B | 1.69B | 1.54B | 1.38B | 1.49B | 0.35B | 0.51B | 0.50B | 0.24B | 0.17B | 0.12B | 48.7B |
| 2025 | 29.2B | 9.42B | 3.10B | 2.26B | 1.50B | 1.51B | 0.85B | 1.36B | 0.67B | 0.47B | 0.23B | 0.15B | 0.19B | 50.9B |
| TTM | 115.7B | 38.6B | 12.5B | 7.70B | 6.07B | 5.10B | 4.35B | 2.38B | 2.31B | 1.94B | 0.93B | 0.63B | 0.60B | 198.8B |
| % of Total (TTM) | 58.2% | 19.4% | 6.3% | 3.9% | 3.1% | 2.6% | 2.2% | 1.2% | 1.2% | 1.0% | 0.5% | 0.3% | 0.3% | 100% |
Segment Performance (Axis 2)
No segment data available.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $40,748M |
| 1 | Cash | $3,556M |
| 2 | Total Liabilities | $32,834M |
| 3 | Total Debt | $17,094M |
| 4 | Total Equity | $7,910M |
| 5 | Debt to Equity Ratio | 2.16 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $31.00 | 4.2% | Nicks Growth: 0% Nick's Expected Margin: 5% FINVIZ Growth: 8% |
Nicks: 7 Finviz: 14 |
Nick's: 0.327 | 2.1 | 50.8 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $0.61 EPS | TTM | $3.99 | -87.1% | $8.66 | -72.1% |
| $2.61 EPS | 2025 | $17.06 | -45.0% | $37.05 | 19.5% |
| $2.73 EPS | 2026 | $17.84 | -42.5% | $38.75 | 25.0% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 20.28% | 1.05% | 20.01% | 0.45% | 1.20% | 1.93% | 21.82% | 5.28% | 78.9% | 94.4% |
| 3 Years | 20.28% | 1.05% | 20.01% | 0.45% | 1.20% | 1.93% | 21.82% | 5.28% | 78.9% | 94.4% |
| 5 Years | 20.28% | 1.05% | 20.01% | 0.45% | 1.20% | 1.93% | 21.82% | 5.28% | 78.9% | 94.4% |
| 10 Years | 20.28% | 1.05% | 20.01% | 0.45% | 1.20% | 1.93% | 21.82% | 5.28% | 78.9% | 94.4% |